CD36

Summary

CD36 (CD36 molecule (CD36 blood group), HGNC:1663) is a protein-coding gene on chromosome 7q21.11, encoding Platelet glycoprotein 4 (P16671). Multifunctional glycoprotein that acts as a receptor for a broad range of ligands.

The protein encoded by this gene is the fourth major glycoprotein of the platelet surface and serves as a receptor for thrombospondin in platelets and various cell lines. Since thrombospondins are widely distributed proteins involved in a variety of adhesive processes, this protein may have important functions as a cell adhesion molecule. It binds to collagen, thrombospondin, anionic phospholipids and oxidized LDL. It directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes and it binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid transport. Mutations in this gene cause platelet glycoprotein deficiency. Multiple alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 948 — RefSeq curated summary.

At a glance

• Gene–disease (curated): platelet-type bleeding disorder 10 (Strong, GenCC)
• GWAS associations: 45
• Clinical variants (ClinVar): 341 total — 29 pathogenic, 32 likely-pathogenic
• Phenotypes (HPO): 5
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity unscored
• MANE Select transcript: NM_001001548

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1663
Approved symbol	CD36
Name	CD36 molecule (CD36 blood group)
Location	7q21.11
Locus type	gene with protein product
Status	Approved
Aliases	SCARB3, GPIV, FAT, GP4, GP3B, GPIIIB
Ensembl gene	ENSG00000135218
Ensembl biotype	protein_coding
OMIM	173510
Entrez	948

Gene structure

Transcript identifiers

Ensembl transcripts: 120 — 113 protein_coding, 4 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000309881, ENST00000394788, ENST00000413265, ENST00000419819, ENST00000426978, ENST00000428497, ENST00000432207, ENST00000433696, ENST00000435819, ENST00000436384, ENST00000438020, ENST00000441034, ENST00000441109, ENST00000447544, ENST00000464213, ENST00000478292, ENST00000480599, ENST00000482059, ENST00000488048, ENST00000526804, ENST00000534394, ENST00000538969, ENST00000544133, ENST00000648416, ENST00000855923, ENST00000855924, ENST00000855925, ENST00000855926, ENST00000855927, ENST00000855928, ENST00000855929, ENST00000855930, ENST00000855931, ENST00000855932, ENST00000855933, ENST00000855934, ENST00000855935, ENST00000855936, ENST00000855937, ENST00000855938, ENST00000855939, ENST00000855940, ENST00000855941, ENST00000855942, ENST00000855943, ENST00000855944, ENST00000855945, ENST00000855946, ENST00000855947, ENST00000855948, ENST00000855949, ENST00000855950, ENST00000855951, ENST00000855952, ENST00000855953, ENST00000855954, ENST00000855955, ENST00000855956, ENST00000855957, ENST00000855958, ENST00000855959, ENST00000855960, ENST00000855961, ENST00000855962, ENST00000855963, ENST00000855964, ENST00000855965, ENST00000855966, ENST00000956914, ENST00000956915, ENST00000956916, ENST00000956917, ENST00000956918, ENST00000956919, ENST00000956920, ENST00000956921, ENST00000956922, ENST00000956923, ENST00000956924, ENST00000956925, ENST00000956926, ENST00000956927, ENST00000956928, ENST00000956929, ENST00000956930, ENST00000956931, ENST00000956932, ENST00000956933, ENST00000956934, ENST00000956935, ENST00000956936, ENST00000956937, ENST00000956938, ENST00000956939, ENST00000956940, ENST00000956941, ENST00000956942, ENST00000956943, ENST00000956944, ENST00000956945, ENST00000956946, ENST00000956947, ENST00000956948, ENST00000956949, ENST00000956950, ENST00000956951, ENST00000956952, ENST00000956953, ENST00000956954, ENST00000956955, ENST00000956956, ENST00000956957, ENST00000956958, ENST00000956959, ENST00000956960, ENST00000956961, ENST00000956962, ENST00000956963, ENST00000956964, ENST00000956965

RefSeq mRNA: 15 — MANE Select: NM_001001548 NM_000072, NM_001001547, NM_001001548, NM_001127443, NM_001127444, NM_001289908, NM_001289909, NM_001289911, NM_001371074, NM_001371075, NM_001371077, NM_001371078, NM_001371079, NM_001371080, NM_001371081

CCDS: CCDS34673, CCDS78249, CCDS78250, CCDS78251

Canonical transcript exons

ENST00000447544 — 15 exons

Exon	Start	End
ENSE00000698626	80666443	80666489
ENSE00000877067	80669953	80670022
ENSE00000877068	80670977	80671164
ENSE00001420198	80646088	80646181
ENSE00001519578	80673983	80674147
ENSE00001934020	80676384	80679274
ENSE00003463166	80672770	80672843
ENSE00003549922	80671922	80672040
ENSE00003610329	80673355	80673409
ENSE00003659355	80664406	80664497
ENSE00003685903	80646652	80646860
ENSE00003785604	80661063	80661210
ENSE00003785903	80656540	80656700
ENSE00003789131	80662990	80663169
ENSE00003844768	80638642	80638746

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 99.61.

FANTOM5 (CAGE): breadth broad, TPM avg 105.2832 / max 8849.2525, expressed in 913 samples.

FANTOM5 promoters (44 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79306	80.3204	631
79307	11.7376	464
79312	2.6545	53
79295	2.1448	258
79305	0.6555	130
79293	0.6409	83
79291	0.6084	80
79289	0.5808	73
79303	0.5022	59
79290	0.4671	71

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adipose tissue of abdominal region	UBERON:0007808	99.61	gold quality
omental fat pad	UBERON:0010414	99.60	gold quality
monocyte	CL:0000576	99.55	gold quality
adipose tissue	UBERON:0001013	99.53	gold quality
jejunal mucosa	UBERON:0000399	99.47	gold quality
peritoneum	UBERON:0002358	99.44	gold quality
heart right ventricle	UBERON:0002080	99.42	gold quality
mononuclear cell	CL:0000842	99.33	gold quality
subcutaneous adipose tissue	UBERON:0002190	99.28	gold quality
left ventricle myocardium	UBERON:0006566	99.25	gold quality
leukocyte	CL:0000738	99.24	gold quality
cardiac ventricle	UBERON:0002082	99.20	gold quality
heart left ventricle	UBERON:0002084	99.20	gold quality
apex of heart	UBERON:0002098	99.09	gold quality
skin of hip	UBERON:0001554	99.02	gold quality
connective tissue	UBERON:0002384	98.89	gold quality
right atrium auricular region	UBERON:0006631	98.79	gold quality
myocardium	UBERON:0002349	98.77	gold quality
cardiac atrium	UBERON:0002081	98.72	gold quality
trabecular bone tissue	UBERON:0002483	98.42	gold quality
vena cava	UBERON:0004087	98.42	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.41	gold quality
heart	UBERON:0000948	98.30	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.30	gold quality
biceps brachii	UBERON:0001507	98.23	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.23	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.16	gold quality
colonic epithelium	UBERON:0000397	98.08	gold quality
buccal mucosa cell	CL:0002336	98.07	gold quality
duodenum	UBERON:0002114	98.07	gold quality

Single-cell (SCXA)

Detected in 23 experiment(s), a significant marker in 20.

Experiment	Marker?	Max mean expression
E-GEOD-81383	yes	5237.96
E-ENAD-20	yes	2859.10
E-HCAD-24	yes	2021.64
E-CURD-11	yes	1889.19
E-MTAB-6701	yes	1697.95
E-MTAB-10553	yes	1548.28
E-GEOD-149689	yes	516.49
E-GEOD-83139	yes	178.53
E-HCAD-4	yes	140.82
E-CURD-122	yes	72.21
E-CURD-112	yes	65.82
E-HCAD-10	yes	53.10
E-MTAB-10042	yes	28.86
E-MTAB-6678	yes	26.03
E-HCAD-9	yes	20.59

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

3 targets.

Target	Regulation
CCL5	Activation
CXCL1	Activation
CXCL2	Activation

Upstream regulators (CollecTRI, top): AEBP1, AHR, CEBPA, CEBPB, CEBPG, GLI2, HIF1A, IL13, IL4, KLF2, NFE2L2, NR1H2, NR1H3, NR1H4, NR1I2, NR2C2, POU2F2, PPARA, PPARD, PPARG, RUNX3, SREBF1, STAT1, STAT5A, TCF3, TCF4, TFAP2A, TFAP2B, TNF

miRNA regulators (miRDB)

42 targeting CD36, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-2113	99.58	71.22	1521
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity Not yet evaluated (unscored). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• novel variants in individuals from malaria-endemic Ghana (PMID:11668637)
• The metabolic role of CD36 was tested by glucose loading in type I or II CD36 deficiency pts. Changes in triglyceride and glucose metabolism were seen in CD36 deficiency due to impaired fast FA clearance by muscle and increased liver FA uptake. (PMID:11686358)
• A redox-dependent conformational fraction of CD36, localized in the CD36 C-terminal cysteine-rich region, mediates cytoadherence of Plasmodium falciparum-infected erythrocytes to CD36-expressing cells and is inducible by low toxicity reducing agents. (PMID:11714819)
• CD36 Pro90Ser mutation is not necessarily related to the insulin resistance syndrome, but is associated with high free fatty acid concentrations in Japanese (PMID:11718687)
• CD36 deficiency induced by antiretroviral therapy. (PMID:11834946)
• promoter structure and trans activation by pparalpha and ppargamma ligands (PMID:11867619)
• Advanced glycation endproducts generated in situ are recognized by CD36, which might contribute to the pathogenesis of diabetic macrovascular complications. (PMID:11872368)
• identification of terminal six amino acids of carboxy cytoplasmic tail as a functional domain implicated in binding and capture of oxidized low-density lipoprotein (PMID:12023894)
• Genomic heterogeneity of type II CD36 deficiency (PMID:12031598)
• Results offer structural insights into the molecular patterns recognized by the scavenger receptor CD36 and provide a platform for the development of potential therapeutic inhibitory agents. (PMID:12105195)
• Heterozygotes, CD36+/-, have a significant reduction of long-chain fatty acids uptake in the heart independent of heart disease, suggesting genotype dependency and that CD36 might be a fundamental determinant of myocardial LCFA uptake. (PMID:12224819)
• Data show that expression of CD36 on platelet membranes was increased in myeloproliferative, but was not significantly different from normal controls in non-insulin-dependent diabetes mellitus. (PMID:12479587)
• mediates nonopsonic phagocytosis of erythrocytes infected with stage I and IIA gametocytes of Plasmodium falciparum in monocytes and macrophages (PMID:12496189)
• Adhesion of dendritic cells derived from CD34+ progenitors to resting human dermal microvascular endothelial cells is down-regulated upon maturation and partially depends on CD11a-CD18, CD11b-CD18 and CD36. (PMID:12516552)
• polySia of milk CD36 is significant for neonatal development in terms of protection and nutrition (PMID:12576469)
• Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on this protein. (PMID:12598312)
• mediates endocytic uptake of advanced glycation end products (PMID:12606036)
• Expression of the monocyte-macrophage LDL scavenger receptor CD36 is increased in people with diabetes mellitus, type 2. (PMID:12618277)
• Expression in melanoma cells is regulated by NSAIDs. (PMID:12664607)
• TSP-1-induced inhibition of megakaryocytopoiesis is probably mediated in part by the binding of TSP-1 to CD36 expressed on the megakaryocytic progenitors (PMID:12679131)
• data suggest that platelet Cd36 has a key role in VLDL-induced collagen-mediated platelet aggregation, possibly contributing to atherothrombosis associated with increased VLDL levels (PMID:12716760)
• Lipoprotein abnormalities in human genetic CD36 deficiency is associated with insulin resistance and abnormal fatty acid metabolism. (PMID:12716848)
• Expression of CD36 mRNA was up-regulated by mildly- and moderately-oxLDL, but not highly-oxLDL. (PMID:12801610)
• CD36 is localized in lipid rafts but not in caveolae, and binding of OxLDL to CD36 leads to endocytosis through a lipid raft pathway (PMID:12947091)
• CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein (PMID:12968020)
• Higher levels of fatty acid translocase/CD36 in human female liver may aid sexually dimorphic development of diseases resulting from or characterized by disturbances in lipid metabolism, such as arteriosclerosis, hyperlipidemia, and insulin resistance. (PMID:14684613)
• there is a CD36-dependent signaling cascade initiated by fibrillar amyloid species that may promote atherogenesis (PMID:14699114)
• CD36 ribozyme specifically suppresses CD36 gene expression and growth in osteosarcoma csell lines. (PMID:14719070)
• CD36 colocalizes with caveolin-3, suggesting that caveolae may regulate cellular fatty acid uptake by CD36. CD36 expression is higher in type 1 compared with type 2 fibers, whereas caveolin-3 expression is significantly higher in type 2 than in type 1 (PMID:14729862)
• CD36 was reactive with microvascular endothelium and adipocytes.Its expression on these high endothelial cells suggest that it participate in trafficking of leukocytes,especially lymphocytes to the omentum. (PMID:15048167)
• CD36 is regulated by estrogen receptors in breast cancer cells (PMID:15050739)
• CD36 has a role in beta-amyloid deposition but not with Alzheimer’s disease (PMID:15059642)
• Promoter polymorphism in CD36 is associated with atherogenesis is french population. (PMID:15064117)
• Redistribution of FAT/CD36 to the sarcolemma may contribute to the etiology of insulin resistance in human muscle. (PMID:15132977)
• A rare CD36 nonsense mutation found in a Caucasian pedigree with autosomal dominant type II diabetes. (PMID:15221799)
• Single Nucleotide Polymorphisms in CD36 Antigens is associated with cardiovascular diseases (PMID:15282206)
• In patients with type I CD36 deficiency, immunization with CD36 antigen by transfusion, can produce anti-CD36 antibody, and potentially lead to platelet transfusion refractoriness or post-tansfusion purpur (PMID:15339698)
• host membrane proteins such as AE1 contribute to the adhesion of malaria-infected erythrocytes to CD36 (PMID:15478802)
• Single nucleotide polymorphism promoter mutation in the CD36 gene represents a putative genetic marker for insulin-resistance in the French population. (PMID:15671915)
• CD36 activity appears important for uptake of fatty acids into beta-cells as well as for mediating their modulatory effects on insulin secretion. (PMID:15677505)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	cd36	ENSDARG00000032639
mus_musculus	Cd36	ENSMUSG00000002944
rattus_norvegicus	Cd36-ps1	ENSRNOG00000005906
rattus_norvegicus		ENSRNOG00000073733
rattus_norvegicus		ENSRNOG00000078327
rattus_norvegicus		ENSRNOG00000090226
caenorhabditis_elegans		WBGENE00013039
caenorhabditis_elegans		WBGENE00013578
caenorhabditis_elegans		WBGENE00015389

Paralogs (2): SCARB1 (ENSG00000073060), SCARB2 (ENSG00000138760)

Protein

Protein identifiers

Platelet glycoprotein 4 — P16671 (reviewed: P16671)

Alternative names: Fatty acid translocase, Glycoprotein IIIb, Leukocyte differentiation antigen CD36, PAS IV, PAS-4, Platelet collagen receptor, Platelet glycoprotein IV, Thrombospondin receptor

All UniProt accessions (11): A4D1B1, E7ERZ9, E7EU05, E7EVU1, E7EWI4, E7EX47, P16671, E9PC45, E9PJX8, E9PLT1, H0YEE7

UniProt curated annotations — full annotation on UniProt →

Function. Multifunctional glycoprotein that acts as a receptor for a broad range of ligands. Ligands can be of proteinaceous nature like thrombospondin, fibronectin, collagen or amyloid-beta as well as of lipidic nature such as oxidized low-density lipoprotein (oxLDL), anionic phospholipids, long-chain fatty acids and bacterial diacylated lipopeptides. They are generally multivalent and can therefore engage multiple receptors simultaneously, the resulting formation of CD36 clusters initiates signal transduction and internalization of receptor-ligand complexes. The dependency on coreceptor signaling is strongly ligand specific. Cellular responses to these ligands are involved in angiogenesis, inflammatory response, fatty acid metabolism, taste and dietary fat processing in the intestine. Binds long-chain fatty acids and facilitates their transport into cells, thus participating in muscle lipid utilization, adipose energy storage, and gut fat absorption. Mechanistically, palmitoylated CD36 captures fatty acids on the cell surface, the binding of fatty acids activates downstream kinase LYN, which phosphorylates the palmitoyltransferase ZDHHC5 and inactivates it, resulting in the subsequent depalmitoylation of CD36, a step needed to initiate the endocytic process and delivery of fatty acids into the cell. In the small intestine, plays a role in proximal absorption of dietary fatty acid and cholesterol for optimal chylomicron formation, possibly through the activation of MAPK1/3 (ERK1/2) signaling pathway. Involved in oral fat perception and preferences. Detection into the tongue of long-chain fatty acids leads to a rapid and sustained rise in flux and protein content of pancreatobiliary secretions. In taste receptor cells, mediates the induction of an increase in intracellular calcium levels by long-chain fatty acids, leading to the activation of the gustatory neurons in the nucleus of the solitary tract. Important factor in both ventromedial hypothalamus neuronal sensing of long-chain fatty acid and the regulation of energy and glucose homeostasis. Receptor for thrombospondins, THBS1 and THBS2, mediating their antiangiogenic effects. Involved in inducing apoptosis in podocytes in response to elevated free fatty acids, acting together with THBS1. As a coreceptor for TLR4:TLR6 heterodimer, promotes inflammation in monocytes/macrophages. Upon ligand binding, such as oxLDL or amyloid-beta 42, interacts with the heterodimer TLR4:TLR6, the complex is internalized and triggers inflammatory response, leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion, through the priming and activation of the NLRP3 inflammasome. Selective and nonredundant sensor of microbial diacylated lipopeptide that signal via TLR2:TLR6 heterodimer, this cluster triggers signaling from the cell surface, leading to the NF-kappa-B-dependent production of TNF, via MYD88 signaling pathway and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. (Microbial infection) Directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes and the internalization of particles independently of TLR signaling.

Subunit / interactions. Interacts with THBS1 and THBS2; the interactions mediate the THBS antiangiogenic activity. Upon interaction with a ligand, such as oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42, rapidly forms a complex with TLR4 and TLR6; the complex is internalized and triggers an inflammatory signal. Through its C-terminus, interacts with PTK2, PXN and LYN, but not with SRC. LYN kinase activity is required for facilitating TLR4:TLR6 heterodimerization and signal initiation. Upon interaction with ligands such as diacylated lipopeptides, interacts with the TLR2:TLR6 heterodimer. Interacts with CD9, CD81, FCER1G, ITGB2 and/or ITGB2; forming a membrane heteromeric complex required for the internalization of CD36 and its ligands. Interacts (when palmitoylated) with ARF6; this interaction mediates CD36 transport to the plasma membrane. (Microbial infection) Binds to Plasmodium falciparum EMP1.

Subcellular location. Cell membrane. Membrane raft. Golgi apparatus. Apical cell membrane.

Post-translational modifications. N-glycosylated and O-glycosylated with a ratio of 2:1. Palmitoylated by ZDHHC5. Palmitoylation is required for proper localization at the plasma membrane. Ubiquitinated at Lys-469 and Lys-472. Ubiquitination is induced by fatty acids such as oleic acid and leads to degradation by the proteasome. Ubiquitination and degradation are inhibited by insulin which blocks the effect of fatty acids.

Disease relevance. Platelet glycoprotein IV deficiency (PG4D) [MIM:608404] A disorder characterized by macrothrombocytopenia without notable hemostatic problems and bleeding tendency. Platelet glycoprotein IV deficiency can be divided into 2 subgroups. The type I phenotype is characterized by platelets and monocytes/macrophages exhibiting complete CD36 deficiency. The type II phenotype lacks the surface expression of CD36 in platelets, but expression in monocytes/macrophages is near normal. The disease is caused by variants affecting the gene represented in this entry. Patients also have postprandial hypertriglyceridemia, insulin resistance and hypertension increasing atherosclerotic risk. Coronary heart disease 7 (CHDS7) [MIM:610938] A multifactorial disease characterized by an imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. Decreased capacity of the coronary vessels is often associated with thickening and loss of elasticity of the coronary arteries. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Polymorphism. Genetic variations in CD36 are involved in susceptibility to malaria and influence the severity and outcome of malaria infection [MIM:611162].

Similarity. Belongs to the CD36 family.

Isoforms (4)

UniProt ID	Names	Canonical?
P16671-1	1	yes
P16671-2	2, ex8-del
P16671-3	3, ex6-7-del
P16671-4	4, ex4-del

RefSeq proteins (15): NP_000063, NP_001001547, NP_001001548, NP_001120915, NP_001120916, NP_001276837, NP_001276838, NP_001276840, NP_001358003, NP_001358004, NP_001358006, NP_001358007, NP_001358008, NP_001358009, NP_001358010 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002159	CD36_fam	Family
IPR005428	CD36/SCARB1/SNMP1	Family

Pfam: PF01130

Catalyzed reactions (Rhea), 10 shown:

• (9Z)-octadecenoate(out) = (9Z)-octadecenoate(in) (RHEA:33655)
• a fatty acid(in) = a fatty acid(out) (RHEA:38879)
• a long-chain fatty acid(out) = a long-chain fatty acid(in) (RHEA:39283)
• octadecanoate(in) = octadecanoate(out) (RHEA:39807)
• butanoate(out) = butanoate(in) (RHEA:45248)
• tetradecanoate(out) = tetradecanoate(in) (RHEA:45252)
• hexadecanoate(out) = hexadecanoate(in) (RHEA:45256)
• tetracosanoate(out) = tetracosanoate(in) (RHEA:45260)
• (9Z,12Z)-octadecadienoate(out) = (9Z,12Z)-octadecadienoate(in) (RHEA:45264)
• (5Z,8Z,11Z,14Z)-eicosatetraenoate(out) = (5Z,8Z,11Z,14Z)-eicosatetraenoate(in) (RHEA:71395)

UniProt features (98 total): strand 23, helix 18, sequence variant 11, glycosylation site 10, turn 6, lipid moiety-binding region 4, splice variant 4, mutagenesis site 4, topological domain 3, disulfide bond 3, sequence conflict 3, cross-link 2, transmembrane region 2, region of interest 2, initiator methionine 1, chain 1, site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5LGD	X-RAY DIFFRACTION	2.07

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P16671-F1	94.14	0.84

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 463 (critical for tlr4-tlr6 dimerization and signaling)

Post-translational modifications (6): 3, 7, 464, 466, 469, 472

Disulfide bonds (3): 243–311, 272–333, 313–322

Glycosylation sites (10): 79, 102, 134, 163, 205, 220, 235, 247, 321, 417

Mutagenesis-validated functional residues (4):

Position	Phenotype
462–472	no effect on cell surface location. loss of oxldl-induced nf-kappa-b activation.
463	no effect on cell surface location. loss of oxldl-induced nf-kappa-b activation. loss of complex formation with tlr4 and
464	no effect on cell surface location, nor on oxldl-induced nf-kappa-b activation.
469–472	abolishes ubiquitination induced by lipids. enhances fatty acid uptake.

Function

Pathways and Gene Ontology

Reactome pathways

47 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation
R-HSA-1236973	Cross-presentation of particulate exogenous antigens (phagosomes)
R-HSA-1236974	ER-Phagosome pathway
R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane
R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade
R-HSA-1989781	PPARA activates gene expression
R-HSA-3000471	Scavenging by Class B Receptors
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-434313	Intracellular metabolism of fatty acids regulates insulin secretion
R-HSA-5602498	MyD88 deficiency (TLR2/4)
R-HSA-5603041	IRAK4 deficiency (TLR2/4)
R-HSA-5686938	Regulation of TLR by endogenous ligand
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-6798695	Neutrophil degranulation
R-HSA-9841922	MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
R-HSA-109582	Hemostasis
R-HSA-1236975	Antigen processing-Cross presentation
R-HSA-1266738	Developmental Biology
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-1280218	Adaptive Immune System
R-HSA-1430728	Metabolism
R-HSA-163685	Integration of energy metabolism
R-HSA-1643685	Disease
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-168898	Toll-like Receptor Cascades
R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade
R-HSA-212165	Epigenetic regulation of gene expression

MSigDB gene sets: 688 (showing top): GOBP_CELLULAR_RESPONSE_TO_LIPOPROTEIN_PARTICLE_STIMULUS, REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, GOBP_DIGESTION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_REGULATION_OF_LIPID_STORAGE, REACTOME_INNATE_IMMUNE_SYSTEM, CHIBA_RESPONSE_TO_TSA_UP, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY, GOBP_REGULATION_OF_WOUND_HEALING, GOBP_CIRCULATORY_SYSTEM_PROCESS, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE

GO Biological Process (85): negative regulation of transcription by RNA polymerase II (GO:0000122), MAPK cascade (GO:0000165), positive regulation of cell-matrix adhesion (GO:0001954), production of molecular mediator involved in inflammatory response (GO:0002532), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631), receptor-mediated endocytosis (GO:0006898), phagocytosis, recognition (GO:0006910), phagocytosis, engulfment (GO:0006911), inflammatory response (GO:0006954), cell adhesion (GO:0007155), cell surface receptor signaling pathway (GO:0007166), positive regulation of cytosolic calcium ion concentration (GO:0007204), blood coagulation (GO:0007596), positive regulation of gene expression (GO:0010628), negative regulation of gene expression (GO:0010629), positive regulation of macrophage derived foam cell differentiation (GO:0010744), positive regulation of cholesterol storage (GO:0010886), fatty acid transport (GO:0015908), long-chain fatty acid transport (GO:0015909), long-chain fatty acid import across plasma membrane (GO:0015911), short-chain fatty acid transport (GO:0015912), negative regulation of angiogenesis (GO:0016525), lipid storage (GO:0019915), obsolete cGMP-mediated signaling (GO:0019934), positive regulation of blood coagulation (GO:0030194), intestinal cholesterol absorption (GO:0030299), cholesterol transport (GO:0030301), receptor internalization (GO:0031623), regulation of lipopolysaccharide-mediated signaling pathway (GO:0031664), positive regulation of interleukin-1 beta production (GO:0032731), positive regulation of interleukin-12 production (GO:0032735), positive regulation of interleukin-6 production (GO:0032755), positive regulation of tumor necrosis factor production (GO:0032760), response to lipid (GO:0033993), regulation of toll-like receptor signaling pathway (GO:0034121), positive regulation of toll-like receptor 4 signaling pathway (GO:0034145), triglyceride transport (GO:0034197), plasma lipoprotein particle clearance (GO:0034381), low-density lipoprotein particle clearance (GO:0034383)

GO Molecular Function (18): amyloid-beta binding (GO:0001540), low-density lipoprotein particle receptor activity (GO:0005041), scavenger receptor activity (GO:0005044), long-chain fatty acid transmembrane transporter activity (GO:0005324), high-density lipoprotein particle binding (GO:0008035), lipid binding (GO:0008289), short-chain fatty acid transmembrane transporter activity (GO:0015636), low-density lipoprotein particle binding (GO:0030169), Toll-like receptor binding (GO:0035325), cargo receptor activity (GO:0038024), protein-containing complex binding (GO:0044877), transforming growth factor beta binding (GO:0050431), thrombospondin receptor activity (GO:0070053), lipoteichoic acid immune receptor activity (GO:0070892), lipoprotein particle binding (GO:0071813), oxidised low-density lipoprotein particle receptor activity (GO:0150025), oleate transmembrane transporter activity (GO:1901480), protein binding (GO:0005515)

GO Cellular Component (18): obsolete extracellular space (GO:0005615), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), caveola (GO:0005901), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), membrane (GO:0016020), endocytic vesicle membrane (GO:0030666), platelet alpha granule membrane (GO:0031092), brush border membrane (GO:0031526), specific granule membrane (GO:0035579), signaling receptor complex (GO:0043235), membrane raft (GO:0045121), phagocytic vesicle (GO:0045335), cell periphery (GO:0071944), collagen trimer (GO:0005581), apical plasma membrane (GO:0016324), apical part of cell (GO:0045177)

Reactome top-level categories

Rollup of top-17 pathways:

Category	Pathways
Antigen processing-Cross presentation	2
Diseases associated with the TLR signaling cascade	2
Immune System	2
Response to elevated platelet cytosolic Ca2+	1
Toll Like Receptor 4 (TLR4) Cascade	1
Toll Like Receptor TLR1:TLR2 Cascade	1
Toll Like Receptor TLR6:TLR2 Cascade	1
Toll Like Receptor 2 (TLR2) Cascade	1
Regulation of lipid metabolism by PPARalpha	1
Binding and Uptake of Ligands by Scavenger Receptors	1
Adipogenesis	1
Free fatty acids regulate insulin secretion	1
Toll-like Receptor Cascades	1
Signaling by Interleukins	1
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
binding	3
phagocytosis	2
cargo receptor activity	2
gene expression	2
regulation of gene expression	2
lipoprotein particle receptor activity	2
fatty acid transmembrane transporter activity	2
lipoprotein particle binding	2
endocytic vesicle	2
secretory granule membrane	2
protein-containing complex	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
intracellular signaling cassette	1
regulation of cell-matrix adhesion	1
cell-matrix adhesion	1
positive regulation of cell-substrate adhesion	1
inflammatory response	1
multicellular organismal process	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
endocytosis	1
cell recognition	1
plasma membrane invagination	1
defense response	1
cellular process	1
signal transduction	1
regulation of biological quality	1
hemostasis	1
wound healing	1
coagulation	1
positive regulation of macromolecule biosynthetic process	1
negative regulation of macromolecule biosynthetic process	1
macrophage derived foam cell differentiation	1
regulation of macrophage derived foam cell differentiation	1
positive regulation of cell differentiation	1
cholesterol storage	1

Protein interactions and networks

STRING

5204 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD36	TLR2	O60603	996
CD36	THBS1	P07996	996
CD36	TLR4	O00206	996
CD36	CD47	Q08722	994
CD36	GP2	P55259	994
CD36	TLR6	Q9Y2C9	993
CD36	GP5	P40197	991
CD36	CD163	Q86VB7	976
CD36	LYN	P07948	973
CD36	FYN	P06241	958
CD36	CAV1	Q03135	956
CD36	THBS2	P35442	954
CD36	TLR1	Q15399	930
CD36	APOB	P04114	917
CD36	FCGR3A	P08637	916
CD36	FCGR3B	O75015	916

IntAct

26 interactions, top by confidence:

A	B	Type	Score
THBS1	CD36	psi-mi:“MI:0407”(direct interaction)	0.560
CD36	UNG	psi-mi:“MI:0915”(physical association)	0.560
APP	CD36	psi-mi:“MI:0915”(physical association)	0.560
CD36	LYN	psi-mi:“MI:0915”(physical association)	0.500
LYN	CD36	psi-mi:“MI:0915”(physical association)	0.500
CD36	LYN	psi-mi:“MI:0914”(association)	0.500
CD36	PXN	psi-mi:“MI:0914”(association)	0.460
Scarb2	CD36	psi-mi:“MI:0915”(physical association)	0.400
CHRD	CD36	psi-mi:“MI:0915”(physical association)	0.370
CD36	TLR4	psi-mi:“MI:0914”(association)	0.350
CAND1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
CD36	TTMP	psi-mi:“MI:0914”(association)	0.350
	VPS37C	psi-mi:“MI:0914”(association)	0.350
SMPD2	A2ML1	psi-mi:“MI:0914”(association)	0.350
CD36	dacD	psi-mi:“MI:0915”(physical association)	0.000
CD36	icc	psi-mi:“MI:0915”(physical association)	0.000
yapE	CD36	psi-mi:“MI:0915”(physical association)	0.000
mpaA	CD36	psi-mi:“MI:0915”(physical association)	0.000
CD36	cutA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (38): CROT (Affinity Capture-MS), C3orf52 (Affinity Capture-MS), MBOAT7 (Affinity Capture-MS), CD36 (Affinity Capture-Western), IRS1 (Affinity Capture-Western), FYN (Affinity Capture-Western), APOB (Reconstituted Complex), GPC4 (Co-localization), GPC4 (Affinity Capture-Western), CD36 (Affinity Capture-Western), HSD11B1 (Reconstituted Complex), LDLR (Reconstituted Complex), VLDLR (Reconstituted Complex), FYN (Affinity Capture-Western), LYN (Affinity Capture-Western)

ESM2 similar proteins: B0X4H5, B2LT48, B2RFN2, B3MTS2, B3P048, B4GMC9, B4IKJ4, B4JG39, B4KB36, B4LYC5, B4NK88, B4PQC2, B4R136, B7Z031, C3U0S3, D2A0H5, E0W3E3, E1JI63, E2IHA6, E5EZW6, E5EZW7, E5EZW9, E5EZX0, O02351, O35114, P16671, P26201, P27615, P70110, P86905, Q07969, Q08857, Q09606, Q11124, Q14108, Q17A88, Q24046, Q27367, Q295A8, Q7Q6R1

Diamond homologs: B2RFN2, C3U0S3, E1JI63, P16671, P26201, P70110, Q07969, Q08857, Q7Q6R1, O18824, O35114, P27615, P97943, Q14108, Q27367, Q60417, Q61009, Q8SQC1, Q8WTV0, Q11124, Q55FQ9, Q9BKJ9, Q9XYS8, P86905

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
CD36	“up-regulates quantity”	“Fatty acid”	relocalization
GRK2	“down-regulates quantity by destabilization”	CD36	phosphorylation
CD36	down-regulates	Angiogenesis
TFEB	“up-regulates quantity by expression”	CD36	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

341 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	29
Likely pathogenic	32
Uncertain significance	184
Likely benign	17
Benign	26

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1301547	NM_001001548.3(CD36):c.667_671dup (p.Ala225fs)	Pathogenic
1322041	NM_001001548.3(CD36):c.638_639del (p.Lys213fs)	Pathogenic
1322043	NM_001001548.3(CD36):c.729C>A (p.Cys243Ter)	Pathogenic
13540	NM_001001548.3(CD36):c.760T>C (p.Phe254Leu)	Pathogenic
13541	NM_001001548.3(CD36):c.1237A>C (p.Ile413Leu)	Pathogenic
1356762	NM_001001548.3(CD36):c.1086_1109dup (p.Tyr370Ter)	Pathogenic
155322	GRCh38/hg38 7q21.11(chr7:80627421-80651297)x1	Pathogenic
1708387	NM_001001548.3(CD36):c.120+1G>A	Pathogenic
285207	NM_001001548.3(CD36):c.1155del (p.Lys385fs)	Pathogenic
3036442	NM_001001548.3(CD36):c.1047_1051dup (p.Pro351fs)	Pathogenic
3062947	GRCh37/hg19 7q21.11(chr7:80107707-80303798)x1	Pathogenic
3374841	NM_001001548.3(CD36):c.1062_1098dup (p.His367delinsArgThrTyrTer)	Pathogenic
3779488	NM_001001548.3(CD36):c.430-1G>C	Pathogenic
3902427	NM_001001548.3(CD36):c.15del (p.Asn6fs)	Pathogenic
4076050	GRCh37/hg19 7q21.11(chr7:80256738-80280613)x1	Pathogenic
4279118	GRCh37/hg19 7q21.11(chr7:80256738-80276756)x1	Pathogenic
4279163	GRCh37/hg19 7q21.11(chr7:80257096-80280613)x1	Pathogenic
442306	GRCh37/hg19 7q21.11(chr7:80256737-80277776)x0	Pathogenic
685689	GRCh37/hg19 7q21.11(chr7:80256254-80276756)x1	Pathogenic
686205	GRCh37/hg19 7q21.11(chr7:80242420-80303812)x1	Pathogenic
686312	GRCh37/hg19 7q21.11(chr7:80262999-80276756)x1	Pathogenic
686525	GRCh37/hg19 7q21.11(chr7:80256737-80276756)x1	Pathogenic
686719	GRCh37/hg19 7q21.11(chr7:80262999-80276756)x1	Pathogenic
686754	GRCh37/hg19 7q21.11(chr7:80254791-80276756)x1	Pathogenic
688139	GRCh37/hg19 7q21.11(chr7:80262999-80276756)x1	Pathogenic
688327	GRCh37/hg19 7q21.11(chr7:80254409-80276756)x1	Pathogenic
688623	GRCh37/hg19 7q21.11(chr7:80256737-80276756)x1	Pathogenic
689019	GRCh37/hg19 7q21.11(chr7:80256888-80276756)x1	Pathogenic
987919	NM_001001547.2:c.(?-183)(120_?)del	Pathogenic
1302074	NM_001001548.3(CD36):c.430-1G>A	Likely pathogenic

SpliceAI

6221 predictions. Top by Δscore:

Variant	Effect	Δscore
7:80414611:A:G	donor_gain	1.0000
7:80458861:CCT:C	acceptor_gain	1.0000
7:80458863:T:C	acceptor_gain	1.0000
7:80462324:C:CT	acceptor_gain	1.0000
7:80462325:A:T	acceptor_gain	1.0000
7:80478839:A:AC	donor_gain	1.0000
7:80478840:C:CC	donor_gain	1.0000
7:80478840:CTAAG:C	donor_gain	1.0000
7:80488533:A:AC	donor_gain	1.0000
7:80488534:C:CT	donor_gain	1.0000
7:80488534:CTG:C	donor_gain	1.0000
7:80488534:CTGCA:C	donor_gain	1.0000
7:80494603:A:AC	donor_gain	1.0000
7:80494604:C:CC	donor_gain	1.0000
7:80541148:G:T	donor_gain	1.0000
7:80656539:GCAA:G	acceptor_gain	1.0000
7:80661049:T:A	acceptor_gain	1.0000
7:80661062:GA:G	acceptor_gain	1.0000
7:80661206:TGGCA:T	donor_gain	1.0000
7:80661207:GGCA:G	donor_gain	1.0000
7:80661207:GGCAG:G	donor_gain	1.0000
7:80661208:GCA:G	donor_gain	1.0000
7:80661208:GCAG:G	donor_gain	1.0000
7:80661209:CAG:C	donor_loss	1.0000
7:80661210:AGT:A	donor_loss	1.0000
7:80661211:G:A	donor_loss	1.0000
7:80661211:G:GG	donor_gain	1.0000
7:80661212:TGA:T	donor_loss	1.0000
7:80661213:G:GC	donor_loss	1.0000
7:80661214:AG:A	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000027409 (7:80663604 G>A), RS1000032231 (7:80679458 T>C), RS1000107107 (7:80659528 C>T), RS1000114141 (7:80637436 C>A), RS1000129194 (7:80628340 C>G,T), RS1000191047 (7:80617349 CA>C,CAA), RS1000270618 (7:80674365 T>C), RS1000297566 (7:80608616 T>G), RS1000338107 (7:80679492 T>A), RS1000347504 (7:80641672 A>G), RS1000432594 (7:80660685 G>A), RS1000440867 (7:80620297 C>T), RS1000465011 (7:80661051 C>A,T), RS1000465877 (7:80629617 A>C,G), RS1000484969 (7:80641376 T>A)

Disease associations

OMIM: gene MIM:173510 | disease phenotypes: MIM:608404, MIM:610938, MIM:611162, MIM:231200, MIM:125853

GenCC curated gene-disease

Disease	Classification	Inheritance
platelet-type bleeding disorder 10	Strong	Autosomal recessive

Mondo (6): platelet-type bleeding disorder 10 (MONDO:0012031), coronary heart disease, susceptibility to, 7 (MONDO:0012585), malaria, susceptibility to (MONDO:0021024), osteopetrosis (MONDO:0017198), inherited bleeding disorder, platelet-type (MONDO:0000009), type 2 diabetes mellitus (MONDO:0005148)

Orphanet (3): Malaria (Orphanet:673), Osteopetrosis and related disorders (Orphanet:2781), Rare hemorrhagic disorder due to a platelet anomaly (Orphanet:248326)

HPO phenotypes

5 total (6 of 5 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0001873	Thrombocytopenia
HP:0001892	Abnormal bleeding
HP:0001902	Giant platelets
HP:0003010	Prolonged bleeding time
HP:0011002	Osteopetrosis

GWAS associations

45 associations (top):

Study	Trait	p-value
GCST000407_1	Left ventricular mass	3.000000e-06
GCST001632_4	Response to fenofibrate	8.000000e-08
GCST002043_2	HDL cholesterol	6.000000e-10
GCST003542_206	Night sleep phenotypes	3.000000e-06
GCST004599_53	Mean platelet volume	5.000000e-12
GCST004601_98	Red blood cell count	2.000000e-12
GCST004602_54	Mean corpuscular volume	1.000000e-13
GCST004603_39	Platelet count	4.000000e-12
GCST005991_90	Platelet count	2.000000e-17
GCST005992_31	Mean corpuscular hemoglobin concentration	4.000000e-11
GCST005999_16	Aspartate aminotransferase levels	3.000000e-14
GCST006005_13	High density lipoprotein cholesterol levels	5.000000e-21
GCST006585_627	Blood protein levels	1.000000e-06
GCST006611_151	HDL cholesterol	3.000000e-27
GCST006804_111	Red cell distribution width	2.000000e-17
GCST008047_5	Platelet count	3.000000e-09
GCST008075_12	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	6.000000e-45
GCST008075_147	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	6.000000e-51
GCST008075_98	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	5.000000e-08
GCST008084_166	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	2.000000e-08
GCST008084_63	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	5.000000e-08
GCST008085_189	HDL cholesterol levels in current drinkers	5.000000e-06
GCST008085_71	HDL cholesterol levels in current drinkers	2.000000e-07
GCST010396_259	Gut microbiota (bacterial taxa, hurdle binary method)	2.000000e-07
GCST010396_277	Gut microbiota (bacterial taxa, hurdle binary method)	4.000000e-06
GCST010796_591	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST011010_14	Electrocardiographic traits (multivariate)	5.000000e-09
GCST011348_13	High density lipoprotein cholesterol levels	1.000000e-18
GCST011351_11	Aspartate aminotransferase levels	1.000000e-12
GCST012032_7	Platelet count	6.000000e-08

EFO canonical traits (14, from GWAS)

EFO ID	Trait name
EFO:0008205	left ventricular structural measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004305	erythrocyte count
EFO:0004309	platelet count
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0004736	aspartate aminotransferase measurement
EFO:0009188	Red cell distribution width
EFO:0004329	alcohol drinking
EFO:0007874	gut microbiome measurement
EFO:0004327	electrocardiography
EFO:0005090	basophil count
EFO:0004509	hemoglobin measurement
EFO:0010701	mean reticulocyte volume
EFO:0007985	platelet crit

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D003924	Diabetes Mellitus, Type 2	C18.452.394.750.149; C19.246.300
D010022	Osteopetrosis	C05.116.099.708.702.678
C564245	Platelet Glycoprotein IV Deficiency (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1744526 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
peptide 1 [PMID: 31774287]	Antagonist	7.1	pKd
compound 3c [PMID: 30360354]	Antagonist	5.6	pIC50

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.40	IC50	4000	nM	CHEMBL6161924

CTD chemical–gene interactions

186 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Rosiglitazone	affects cotreatment, decreases reaction, increases expression, increases reaction, affects reaction (+1 more)	16
bisphenol A	increases methylation, increases activity, increases response to substance, affects reaction, decreases reaction (+2 more)	9
Tetradecanoylphorbol Acetate	affects cotreatment, increases expression, decreases reaction, increases reaction, decreases expression	9
Troglitazone	decreases expression, decreases reaction, increases expression	6
Oleic Acid	affects cotreatment, increases expression, decreases reaction	6
Tetrachlorodibenzodioxin	decreases ubiquitination, decreases reaction, increases expression, affects cotreatment, decreases expression	5
Valproic Acid	decreases reaction, increases expression, increases methylation	5
Palmitic Acid	decreases reaction, increases expression, affects cotreatment, decreases expression	5
Pioglitazone	increases expression, affects reaction, affects cotreatment, decreases expression, decreases reaction	4
Amiodarone	increases expression, decreases expression	4
Aflatoxin B1	decreases expression, decreases methylation, increases expression	4
2-chloro-5-nitrobenzanilide	decreases expression, decreases reaction, affects cotreatment, increases expression	3
Resveratrol	decreases expression, decreases reaction, increases expression	3
Acetylcysteine	increases expression, decreases reaction	3
Dexamethasone	decreases reaction, affects reaction, affects binding, increases reaction, increases expression	3
Estradiol	affects cotreatment, increases expression, decreases expression	3
Quercetin	affects cotreatment, decreases reaction, increases expression, decreases expression	3
Tamoxifen	affects cotreatment, increases expression, decreases reaction, affects binding, decreases expression	3
Tobacco Smoke Pollution	decreases expression	3
fluorotelomer sulfonic acids	increases uptake, decreases expression	2
sodium arsenate	decreases expression, increases abundance	2
perfluorooctanoic acid	increases expression	2
nickel sulfate	decreases expression	2
perfluorooctane sulfonic acid	increases uptake, increases expression	2
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	increases expression, affects cotreatment, decreases reaction	2
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	increases expression, decreases reaction	2
GW 7647	affects cotreatment, increases expression	2
T 0070907	decreases reaction, increases expression	2
15-deoxyprostaglandin J2	increases reaction, affects cotreatment, increases expression	2
bisphenol B	decreases expression, increases expression	2

ChEMBL screening assays

6 unique, capped per target: 5 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1764258	Binding	Antagonist activity at human CD36-oxLDL binding at 1 uM after 2 hrs by ELISA	Synthesis and structure-activity relationship of N-(2-arylethyl) isoquinoline derivatives as human scavenger receptor CD36 antagonists. — Eur J Med Chem
CHEMBL1764260	Functional	Antagonist activity at human CD36 expressed in insect Sf9 cells assessed as inhibition of DiL-acetylated LDL uptake at 10 ug/ml after 5 hrs by fluorometric analysis	Synthesis and structure-activity relationship of N-(2-arylethyl) isoquinoline derivatives as human scavenger receptor CD36 antagonists. — Eur J Med Chem

Cellosaurus cell lines

9 cell lines: 7 cancer cell line, 1 spontaneously immortalized cell line, 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_8848	CHO-CD36	Spontaneously immortalized cell line	Female
CVCL_B5FY	SYSUSCi002-A	Induced pluripotent stem cell	Female
CVCL_B7WH	Abcam Raji CD36 KO	Cancer cell line	Male
CVCL_B9X2	Abcam THP-1 CD36 KO	Cancer cell line	Male
CVCL_C0UP	HP-Nak	Cancer cell line	Female
CVCL_C6Z0	Abcam PC-3 CD36 KO	Cancer cell line	Male
CVCL_E8DS	BPS Bioscience THP-1 CD36 KO	Cancer cell line	Male
CVCL_SH71	HAP1 CD36 (-) 1	Cancer cell line	Male
CVCL_XM58	HAP1 CD36 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT06630572	PHASE4	TERMINATED	Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes
NCT00006163	PHASE4	COMPLETED	Computer-assisted Diabetes Self-management Interventions
NCT00036504	PHASE4	COMPLETED	Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin
NCT00044460	PHASE4	COMPLETED	Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00095446	PHASE4	COMPLETED	NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
NCT00101751	PHASE4	COMPLETED	INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
NCT00110370	PHASE4	COMPLETED	Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
NCT00110448	PHASE4	COMPLETED	Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial
NCT00118950	PHASE4	COMPLETED	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118963	PHASE4	COMPLETED	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
NCT00121966	PHASE4	COMPLETED	South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
NCT00123604	PHASE4	COMPLETED	Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
NCT00123643	PHASE4	COMPLETED	Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
NCT00124397	PHASE4	COMPLETED	Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
NCT00129233	PHASE4	COMPLETED	Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
NCT00133718	PHASE4	COMPLETED	A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
NCT00135070	PHASE4	TERMINATED	Hospital In-Patient Insulin Study
NCT00141232	PHASE4	COMPLETED	Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00144144	PHASE4	UNKNOWN	A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
NCT00149331	PHASE4	COMPLETED	The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy
NCT00162357	PHASE4	COMPLETED	Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
NCT00174681	PHASE4	COMPLETED	Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
NCT00174824	PHASE4	COMPLETED	Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
NCT00177398	PHASE4	COMPLETED	Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings
NCT00179400	PHASE4	COMPLETED	The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
NCT00184561	PHASE4	COMPLETED	Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
NCT00184626	PHASE4	COMPLETED	Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
NCT00191178	PHASE4	COMPLETED	Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes
NCT00191282	PHASE4	COMPLETED	Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
NCT00191464	PHASE4	COMPLETED	Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
NCT00192803	PHASE4	UNKNOWN	Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
NCT00202033	PHASE4	COMPLETED	Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes
NCT00205660	PHASE4	COMPLETED	Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
NCT00212290	PHASE4	COMPLETED	Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212303	PHASE4	COMPLETED	Exercise Training in Type 2 Diabetes and Hypertension
NCT00225342	PHASE4	WITHDRAWN	Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina
NCT00238472	PHASE4	COMPLETED	A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
NCT00239538	PHASE4	COMPLETED	SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
NCT00240253	PHASE4	COMPLETED	A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
NCT00240422	PHASE4	COMPLETED	Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes